1. ABOUT THE DATASET -------------------- Title: Short survey on aspirin use for cancer prevention among the UK general public Creator(s): Kelly E. Lloyd[1], Louise H. Hall[1], Lucy Ziegler[1], Robbie Foy[1], Sophie M. C. Green[1], Mairead MacKenzie[2], David G. Taylor[3], Samuel G. Smith[1] Organisation(s): 1. Leeds Institute of Health Sciences, University of Leeds, Leeds, UK 2. Independent Cancer Patients’ Voice, London, UK 3. School of Pharmacy, University College London, London, UK Rights-holder(s):Unless otherwise stated, Copyright 2023 University of Leeds Publication Year: 2023 Description: In Australia, guidance recommends aspirin for colorectal cancer prevention among people aged 50-70 at population risk. The medication could be offered more widely in the future, such as in the UK and other countries. We recruited 400 UK respondents aged 50-70 through a market research company to an online survey. In the survey, we investigateed aspirin use, and awareness of aspirin for cancer prevention among the UK general population. We also recorded demographic data on the sample. Cite as: Kelly E. Lloyd; Louise H. Hall; Lucy Ziegler; Robbie Foy; Sophie M. C. Green; Mairead MacKenzie; David G. Taylor; Samuel G. Smith (2023): Short survey on aspirin use for cancer prevention among the UK general public. [Dataset]. https://doi.org/10.5518/1379 Related publication: Lloyd, K.E., Hall, L.H., Ziegler, L., Foy, R., Green, S. M. C., MacKenzie M., Taylor D.G., Smith, S. Acceptability of aspirin for cancer preventive therapy: a mixed methods study exploring the views of the UK general population. 2022. In preparation. Contact: Kelly Lloyd, k.e.lloyd@leeds.ac.uk 2. TERMS OF USE --------------- Copyright 2023 University of Leeds. This dataset is licensed under a Creative Commons Attribution 4.0 International Licence: https://creativecommons.org/licenses/by/4.0/.] 3. PROJECT AND FUNDING INFORMATION ---------------------------------- Title: Acceptability of aspirin for cancer preventive therapy: a mixed methods study exploring the views of the UK general population Dates: July to August 2022 Funding organisation: This work is fully funded by the Aspirin for Cancer Prevention AsCaP Group CRUK Grant Code: A24991, Senior Executive Board Prof. J Burn, Prof. A.T Chan, Prof. J Cuzick, Dr. B Nedjai, Prof. Ruth Langley. During the study, KEL was supported by an Economic and Social Research Council studentship [grant number ES/P000745/1]. This report is independent research supported by the National Institute for Health Research NIHR Advanced Fellowship, Dr Samuel Smith, [grant number NIHR300588]. SGS also acknowledges funding support from a Yorkshire Cancer Research University Academic Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. 4. CONTENTS ----------- File listing 1. Short_survey_aspirin_cancer_prevention_among_general public - Raw data in Excel 2. General_public_data_cleaned - Cleaned data in Excel. This dataset was generated by the clean data script in R being applied to the raw dataset. 3. Clean_general_public_data_script - R script to clean data. This file should be applied to the raw dataset. 4. Analyse_general_public_data_script - R script to analyse data, using the clean dataset. Script in R for analysing the data in proportions and frequencies. 5. General_public_PIS_Survey_V.5.docx - Participant information sheet. 6. Aspirin_consent_form_V.4_survey.docx - Consent form. - Number of variables: 28 in raw dataset, and 14 variables in the clean dataset - Number of cases/rows: 400 participants 5. METHODS ---------- We hosted the online survey on Qualtrics. We recruited participants through a market research company (Dynata). We recruited people from the UK general population between the ages of 50 to 70, as the benefits of aspirin for cancer prevention are estimated to be greater than the risks of adverse effects within this age range. The study was preregistered: https://doi.org/10.17605/OSF.IO/3EFG7 We collected data on participants’ current and previous use of aspirin, why they take / had taken aspirin (e.g., for cancer prevention), and their knowledge on the use of aspirin for cancer prevention. Participants were asked 11 questions in the survey: 1. Do you ever take aspirin? a. Yes b. No 2. Do you take aspirin regularly (i.e. most days or every day)? a. Yes b. No c. N/A – do not take aspirin 3. What is the main reason you take aspirin? a. Pain relief b. Prevention of cardiovascular disease (i.e. heart and circulatory disease) c. Prevention of cancer d. Other reason, please specify ______________ e. N/A – do not take aspirin 4. Prior to completing this survey, were you aware that aspirin could reduce the risk of developing certain types of cancers? a. Yes b. No 5. Has your doctor or any other healthcare professional talked to you about how aspirin may lower your risk of developing bowel cancer or any other cancers? a. Yes b. No 6. Have you previously been diagnosed with cancer? a. Yes, please specify which cancer(s): _______________ b. No 7. How would you describe your gender? a. Male b. Female c. Non-binary d. Different identity e. Prefer not to say 8. What is your age? __________________ 9. How would you describe your ethnicity? a. White - English/ Welsh/ Scottish/ Northern Irish/ British b. White - Irish c. White - Gypsy or Irish Traveller d. Any other White background e. Mixed - White and Black Caribbean f. Mixed - White and Black African g. Mixed - White and Asian h. Any other mixed/ multiple ethnic background i. Asian or Asian British - Indian j. Asian or Asian British - Pakistani k. Asian or Asian British - Bangladeshi l. Asian or Asian British - Chinese m. Any other Asian background n. Black or Black British - African o. Black or Black British - Caribbean p. Any other Black/ African/ Caribbean background q. Arab or Arab British r. Any other ethnic group 10. What is the highest level of educational or professional qualification you have obtained? a. GCSE/ O-level/ CSE b. Vocational qualifications (e.g. NVQ1+2) c. A-Level or equivalent (e.g. NVQ3) d. Bachelor’s degree or equivalent (e.g. NVQ4) e. Masters/ PhD or equivalent f. Other qualifications g. No formal qualifications 11. Are you interested in taking part in the follow-up interview study? a. Yes, please provide your contact details (e.g. email, phone number) and we will contact you further about the study: __________________ b. No